drugset / Trial / NCT02614482

Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children.

NCT02614482

Phase 3 Completed 26 enrolled Stéphane Bolduc Pfizer · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long term tolerability of Fesoterodine and its efficacy for overactive bladder syndrome in children.

Timeline

Start
2015-10
Primary completion
2018-06
Completion
2018-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Fesoterodine Other / unclassified 4 mg Oral
Subject Fesoterodine Other / unclassified 8 mg Oral

Indications